<DOC>
	<DOCNO>NCT01147380</DOCNO>
	<brief_summary>The objective study evaluate feasibility safety adoptive transfer activate natural killer ( NK ) cell extract cadaveric donor liver graft perfusate liver transplant recipient hepatocellular carcinoma ( HCC )</brief_summary>
	<brief_title>Safety Study Liver Natural Killer Cell Therapy Hepatoma Liver Transplantation</brief_title>
	<detailed_description>To investigate whether adoptive transfer IL-2 stimulate NKcells extract cadaveric donor liver graft exudate recipient HCC lead prevent recurrence HCC liver transplantation . The method plan use collect NK cell cadaveric donor liver perfusate time organ recovery . The perfusate condense centrifuge liver mononuclear cell ( LMNC ) isolate gradient centrifugation . LMNC culture anti-CD3 antibody . LMNC separted CD3-/CD56+ NK cell fraction non-NK cell fraction . The purity isolate fraction assess Flow cytometric analysis . NK cell culture human recombinant IL-2 10 % RPMI 37 ÂºC 5 % CO2 incubator . NK cell infuse intravenously recipient HCC liver transplant cadaveric donor post operative day 4 attempt prevent metastasis recurrence HCC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Primary liver transplant recipient HCC Patients need meet liver transplant eligibility criterion Cardiac function ; cardiac echo indicate ejection fraction ( EF ) &gt; 35 % right ventricular systolic pressure ( RVSP ) &lt; 50mmHg . Stress echo show ischemic lesion ( applicable ) . Pulmonary function ; SpO2 &gt; 90 % PaO2 &gt; 60 mmHg , CT show active pulmonary lesion . Complete blood count ; Platelet &gt; 20,000 /mm^3 , Hematocrit &gt; 20 % , WBC &gt; 1,000 /mm^3 Eighteen year age old Ability provide inform consent If female childbearing potential : Must lactating , must negative serum Bhuman chorionic gonadotropin ( HCG ) test within 7 day prior Day Transplant , must agree practice acceptable reliable form contraception study Ability provide inform consent Living donor liver transplant ; healthy person donates part liver recipient Multiple organ transplant Prior solid organ bone marrow transplant recipient Fluminant hepatic failure The patient regularly receive hemodialysis twice week liver transplant Status 1 transplant ; acute severe disease define patient recent development liver disease intensive care unit hospital life expectancy without liver transplant few 7 day ABO incompatible transplant Transplants utilize liver nonheart beat donor ; cardiac death donor Recipients investigational therapy within 90 day prior transplant procedure Acute viral illness History malignancy within 5 year , exception : Adequately treat localized squamous basal cell carcinoma skin without evidence recurrence , and/or Hepatocellular carcinoma Illness primary liver disease ( e.g. , severe ischemic heart disease , leave ventricular dysfunction , pulmonary disease ) , , opinion Investigator , may significantly increase risk transplantation procedure Current drug alcohol abuse , opinion Investigator , risk poor compliance ( drug testing require ) Serology positive donor ( HCV , HBsAg , HBcAb , HTLV1 , HTLV3 , EBVIgM ) Poor liver function donor ( Total bilirubin &gt; 3.0 mg/dl , Prothrombin time &gt; 35 sec ) , Patients receive intercurrent chemotherapy time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>